Published May 6, 2021 Permission granted by Eric Kelsic / Dyno Therapeutics
Dyno Therapeutics, a Harvard University spinout working to improve gene therapy, is expanding with $100 million in new funding from tech investor Andreessen Horowitz and several other venture firms.
Since officially launching a year ago, Dyno has struck deals with Novartis, Roche and Sarepta Therapeutics to aid their efforts to develop more efficient delivery of gene therapy. But even after doubling in size to 50 employees, the company hasn t been able to keep up with demand for its services, CEO Eric Kelsic said in an interview. Even though it s in the very beginning, we just had so many folks who want to partner with us, said Kelsic. This is really to meet the demand that we ve seen for partnering and to enable us to both expand our [existing] partnerships, as well as to work with new partners.
• Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
• EyePoint Pharmaceuticals (NASDAQ:EYPT) is likely to report quarterly loss at $0.46 per share on revenue of $7.93 million.
• Fortis (NYSE:FTS) is projected to report quarterly earnings at $0.75 per share on revenue of $2.50 billion.
• Madison Square Garden (NYSE:MSGS) is expected to report quarterly loss at $1.80 per share on revenue of $148.62 million.
• America First Multifamily (NASDAQ:ATAX) is projected to report quarterly earnings at $0.12 per share on revenue of $19.09 million.
• Ardmore Shipping (NYSE:ASC) is estimated to report quarterly loss at $0.31 per share on revenue of $24.86 million.
Urges Shareholders to Vote the WHITE Proxy Card “FOR ALL” Four of MIMEDX’s Director Nominees – Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner
Entirely Reconstituted Board and New Management Team Positioned Company for Long-Term Sustainable Growth; Stock Price Appreciation of 237% Since Timothy Wright Selected as CEO
Virtual Annual Meeting to Be Held on May 27, 2021
MARIETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with its 2021 Annual Meeting of Shareholders (“Annual Meeting”), to be held virtually on May 27, 2021 at 10:00 a.m. Eastern Time at www.cesonlineservices.com/mdxg21 vm. MIMEDX shareholders of record at as of 5:00 p.m. Eastern Time on April 16, 20
Home / Top News / Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing
SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of
10.79% and mean dystrophin expression of 6.55%,
consistently higher than the other SRP-5051 dosing cohorts at 12 weeks and weekly eteplirsen at 24 weeks
Sarepta’s predictive model indicates that